Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Enjoys 87% Profit Jump in 2015
February 1, 2016
- Kyowa Kirin to Forge Stand-Alone Sales Regime in US: 5 Year Plan
February 1, 2016
- Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
February 1, 2016
- FDA OKs Eisai’s Halaven for Liposarcoma
February 1, 2016
- Chugai Positions Mid-Sized Molecule Drugs as Third Pillar of Business, Aims to Produce First Candidate within 3 Years
February 1, 2016
- Chugai Foresees Tepid Growth for Next 3 Years: New Biz Plan
January 29, 2016
- Kadcyla Development for Gastric Cancer Discontinued: Chugai
January 29, 2016
- Chugai Delivers Record Earnings, but Pegasys Falters on IFN-Free Hep C Therapies
January 29, 2016
- Shionogi, Nissan Chemical Ink Collaboration Pact on Antifungals
January 29, 2016
- Sumitomo Dainippon to Revise 5-Year Business Plan
January 29, 2016
- Ferring Empowers Japan Unit, Local Head Mark Noggle Doubles as CEO
January 29, 2016
- Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
January 29, 2016
- Shionogi Files Japan NDA for ADHD Drug Licensed from Shire
January 28, 2016
- Mochida Seeks Adenomyosis Indication for Dinagest
January 28, 2016
- 140 Hep C Patients Receive Viekirax in 1st Month
January 27, 2016
- Mochida Set to Achieve 10 Billion Yen Generic Sales in FY2015
January 27, 2016
- MSD Joins with Venture Capital to Offer BD Support for Health-Tech Startups
January 27, 2016
- Mundipharma to Merge Spectrum Unit in March, Become MAH for Zevalin
January 26, 2016
- Kyowa Kirin to Market Sandoz’s Rituximab Biosimilar in Japan
January 26, 2016
- Dispensing Pharmacies Worried about Reversal of Delivery and NHI Prices Following Re-Pricing of Gilead’s “Huge Seller” Hep C Drugs
January 21, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…